Physician profile
Mary Walker
NPI 1699761619
$1,943.33
in general payments reported to CMS, 2019-2025
18 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $431 · 2023: $521 · 2024: $362 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.23 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $266.92 | 2022-2024 | Rexulti |
| Alkermes, INC. | $175.59 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $157.27 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $138.22 | 2021-2024 | |
| Lundbeck LLC | $93.86 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $91.46 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.41 | 2023-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $77.13 | 2023-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $70.17 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $68.46 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $46.63 | 2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $35.89 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $25.60 | 2023 | Spravato |
| Collegium Pharmaceutical, INC. | $23.87 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.67 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $16.90 | 2025 | Datroway |
| Indivior INC. | $15.05 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.